Fig. 5From: Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapyChanges of hormone levels during therapy in males with first and second-line immunotherapy. FSH levels significantly increased in men in second-line immunotherapy, *p < 0.05. 1L pembrolizumab (n = 7), 2L pembrolizumab (n = 11)Back to article page